🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against drug-resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing worldwide, with figures suggesting more than 82 million infections annually. Particularly high rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Global Access

According to results published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have voiced positive views. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.